Status Quo

No federal law caps what manufacturers charge for drugs in the commercial market. Manufacturers set list prices unilaterally and extend effective exclusivity through secondary patent filings on trivial modifications, a practice known as evergreening; the 12 top-selling drugs average approximately 125 patent applications filed per drug, with the majority submitted after FDA approval [I-MAK, 2022]. Medicare was explicitly prohibited from negotiating prices under the 2003 Medicare Modernization Act; the Inflation Reduction Act of 2022 created negotiation authority, but the statutory caps limit it to 10 drugs in 2026 and 20 per year from 2029 onward, out of more than 20,000 drugs on the market [CMS, 2022]. Pharmacy benefit managers (PBMs), three firms of which control roughly 80% of the market [FTC, 2024], negotiate manufacturer rebates in exchange for formulary placement, but federal law does not require those rebates to flow to patients at the counter; patients pay cost-sharing based on list prices, not net prices, so the rebate that reduced the insurer's cost does nothing for the person at the pharmacy window.

What changed from round 1

• Statutory functional definition of "rebate" added: Round 1 left "rebate" undefined, which means PBMs can reclassify rebate payments as "administrative fees," "data services fees," or "performance guarantees" before the rulemaking is final. A statutory definition now covers any payment, benefit, or credit from a drug manufacturer to a PBM or insurer that is linked, explicitly or implicitly, to formulary placement, market share, prescription volume, or any combination thereof, regardless of the label the parties assign to it. This definition takes effect on enactment, independent of the rulemaking timeline. Both Progressive Democrats and Moderate Democrats flagged this; the FTC's 2022 interim report documented the reclassification pattern at scale.

• Indication-level specification added to Medicare negotiation eligibility: Round 1 left "no FDA-approved therapeutic alternative" undefined as to whether it is evaluated at the drug level or the indication level. A narrow-indication trial could have allowed manufacturers to create a technical "therapeutic alternative" and exit negotiation eligibility at low cost. The revised text specifies that eligibility is evaluated based on the drug's primary approved indication (the indication with the largest Medicare patient population at the time of eligibility review), and that approval of a new indication for a different drug does not create a therapeutic alternative for the primary indication unless the new indication treats the same patient population through a comparable mechanism. This closes the indication carve-out documented in Germany's AMNOG experience and in US orphan drug practice.

• Civil penalty added for formulary disclosure non-compliance: Round 1 had no enforcement penalty on the formulary disclosure requirement. The hospital price transparency precedent (14 percent compliance at initial effective date, rising to 70 percent only after the maximum penalty reached $2 million per year) makes clear that disclosure without escalating penalties produces minimal compliance from large institutional actors. The revised text specifies a civil penalty of $100,000 per annual rate filing that omits required disclosure, and $10,000 per day for each calendar day beyond the filing deadline that the disclosure remains incomplete.

• Formulary stability protection added: Round 1 addressed step-therapy circumvention through the prior authorization exception process, but insurers can bypass step-therapy entirely by removing a drug from formulary at annual renewal rather than triggering a prior authorization event. The revised text adds a formulary stability protection: for any drug that a patient has been continuously taking for 90 days or more at the time of formulary redesign, the insurer must maintain coverage at the same tier or lower for a 12-month transition period. Clinical exceptions use the same 72-hour standard. This closes the non-medical switching circumvention documented in Medicare Part D audits and commercial plan literature.

• Commercial rebate pass-through escalation schedule added: Progressive Democrats wanted the commercial pass-through rate raised to 100 percent. The viability feedback identified a navigation path: a scheduled escalation avoids the premium disruption risk of immediate 100 percent pass-through while giving Progressive Democrats a binding timeline. The revised text sets 80 percent in years 1 to 3 (matching the ACA medical loss ratio precedent), 90 percent in years 4 to 5, and 100 percent at year 6. Moderate Republicans can characterize this as a phase-in consistent with existing precedent; Progressive Democrats get a statutory commitment rather than a permanent lower standard.

• Citizen petition reform added to FDA component: The precedent brief identified citizen petition abuse as the one documented delay mechanism not addressed by increased FDA capacity funding. Brand-name manufacturers file petitions challenging generic applications and trigger FDA response obligations that delay approval by an average of 11 months per petition. The revised text links the citizen petition response deadline to the 24-month ANDA (abbreviated new drug application) hearing trigger: FDA must resolve any citizen petition filed against a pending generic application within 120 days if that application has been pending for more than 18 months.

• Pharmacist workflow requirement added to gag clause provision: The gag clause prohibition was legally sound in round 1 but produced only partial behavioral uptake without a workflow requirement, per the 2022 JAMA analysis finding 25 percent proactive disclosure in eligible interactions. The revised text adds a patient-notification workflow requirement: when a patient is picking up a prescription, the dispensing system must generate a prompt to the pharmacist when the cash price at that pharmacy is lower than the patient's cost-sharing under their plan. The pharmacist must disclose the lower option. This converts the legal right into a systematic practice.

• IP protection clause and defined annual negotiation limit added for Conservative Republicans: Conservative Republicans requested an explicit intellectual property protection clause and a defined limit on simultaneous active negotiations. The revised text adds a clause affirming that the Medicare negotiation process does not alter a manufacturer's patent rights, trigger compulsory licensing, or modify any exclusivity period under federal patent or regulatory law. It also establishes a publication requirement: CMS must publish an annual priority queue for drug negotiations, and no more than 50 drugs may be in active negotiation simultaneously. The queue is public and updated annually.

• Small-manufacturer carve-out added to PBM disclosure requirement: Moderate Republicans asked that the PBM disclosure requirement exclude emerging biotech developers who are not the target of the reform. The revised text exempts manufacturers with fewer than $200 million in annual U.S. net revenues from the quarterly PBM contract disclosure filing requirement. The PBM itself remains obligated to disclose regardless of manufacturer size; the exemption relieves small developers from participating in a disclosure process designed around the three dominant PBMs.

Will this hold?

Political sustainability: The PBM transparency provisions remain the durable core. Both parties have sponsored versions of these reforms; the attack surface is narrow because PBMs are unpopular across the political spectrum. The round 2 additions strengthen this core rather than complicating it. The pharmacist workflow requirement is the kind of visible consumer protection that is politically difficult to run against publicly.

The commercial pass-through escalation schedule is the new legislative vulnerability. The pharmaceutical industry and insurer lobbying apparatus will frame the 100 percent endpoint as a premium-raising mandate, targeting it at Moderate Republican co-sponsors before year 4 when the 90 percent step occurs. The six-year phase-in blunts the immediate attack by demonstrating managed transition, but the attack vector shifts to election-cycle timing: opponents will argue that the escalation should be paused or reversed during the year-4 and year-6 election cycles when the PBM contract restructuring deadlines create visible market activity. The strongest defense is the HHS annual premium impact report (flagged as a round-3 priority): without that data, opponents can assert premium harm without contradiction.

The Medicare negotiation expansion remains the primary electoral target for the pharmaceutical industry's advertising campaign, unchanged from round 1. The IP clause and 50-drug cap give Moderate Republican co-sponsors a more defensible position in primary challenges, but the seven-year reauthorization fight remains the mechanism opponents will invest in. The formulary stability protection is low-conflict in public messaging but will generate insurer compliance litigation, particularly from self-insured employer plans that claim ERISA authority.

Structural dependency: The rebate pass-through audit and formulary transparency enforcement remain jointly dependent on the standardized HHS disclosure format, which will not be operational until approximately 2028-2029 based on the CAA 2026 rulemaking timeline. The statutory functional definition of rebate operative on enactment partially closes this gap: even before the format exists, PBMs that reclassify payments face civil liability. But systematic auditing of the pass-through compliance is not possible until the format is live. The step-therapy and formulary stability exception process has a new conditional dependency: the standalone HHS portal funded from civil penalty revenues is contingent on penalty revenues accruing. If compliance is high (penalties are low), the portal lacks its funding source in the transition years. The statute should have a floor funding appropriation.

This policy area addresses prescription drug pricing and the pharmacy benefit management system, expanding Medicare's negotiating power, requiring rebates to flow to patients, and accelerating generic competition.

What Changes

• PBMs must show their math: Pharmacy benefit managers collect billions in manufacturer payments each year and are not currently required to disclose how much they keep versus how much flows to insurers or patients. Three firms control 80 percent of the U.S. market and operate under contracts that are completely opaque to regulators and the public. Under this reform, every PBM must file quarterly reports to HHS disclosing, for each drug, the gross list price, the total manufacturer payment received, and how much was passed to insurers versus retained. "Rebate" is defined in statute to cover any payment linked to formulary placement, market share, or prescription volume, regardless of what the PBM calls it. PBMs cannot rename these payments as "administrative fees" or "data services fees" to escape the requirement. Reports are public within 60 days of each quarter.

• Rebates flow to patients at the pharmacy counter, not to PBMs and insurers: Patients currently pay cost-sharing based on a drug's list price, even when their insurer received a large manufacturer rebate that reduced what the insurer actually paid. The rebate saves the insurer money but does nothing for the person at the pharmacy window. Under this reform, Medicare Part D and Medicaid managed care plans must pass 100 percent of manufacturer rebates through to enrollees as a point-of-sale discount, applied directly against the patient's cost-sharing. Commercial health plans follow a phased schedule: 80 percent in years 1 through 3, 90 percent in years 4 and 5, and 100 percent beginning in year 6. The schedule is written into statute, so a future administration cannot reset it through rulemaking.

• Pharmacists must tell patients when paying cash costs less: Federal law prohibited pharmacists from volunteering that information under gag clauses in PBM contracts, and even after those clauses were banned, only about 25 percent of pharmacists proactively told patients when cash was cheaper. Under this reform, gag clauses are prohibited and unenforceable. More importantly, when a patient picks up a prescription, the pharmacy dispensing system must generate a prompt to the pharmacist whenever the cash price at that pharmacy is lower than the patient's cost-sharing. The pharmacist must then disclose the cheaper option. The disclosure is system-generated, not reliant on the pharmacist remembering.

• Medicare can negotiate prices for drugs with no competition: Medicare was explicitly barred from negotiating drug prices under the 2003 Medicare Modernization Act. The Inflation Reduction Act restored limited authority but capped it at 10 drugs in 2026, rising to 20 per year from 2029, out of more than 20,000 drugs on the market. Under this reform, the annual cap is removed. Medicare can negotiate prices for any drug that has no FDA-approved therapeutic alternative for its primary indication and has faced no generic or biosimilar competition in the prior 36 months. The negotiated ceiling applies to Medicare and Medicaid purchases. It cannot go below 120 percent of the average net price paid by Australia, Canada, France, Germany, and Japan. Manufacturers that refuse to negotiate face an excise tax escalating from 65 percent in year one to 95 percent in year two and beyond. An explicit clause confirms the process does not alter any manufacturer's patent rights, does not trigger compulsory licensing, and does not modify any exclusivity period. No more than 50 drugs may be in active negotiation simultaneously; CMS publishes the priority queue annually.

• Generic drugs can reach the market faster: When a brand-name drug's patent expires, generic competition often takes years to arrive because FDA's generic review office is underfunded and backlogged, and because brand-name manufacturers routinely file citizen petitions challenging generic applications, which delays approval by an average of 11 months per petition. Under this reform, FDA's Office of Generic Drugs receives $800 million over five years, funded by a fee on brand-name manufacturers whose drugs have no approved generic after patent expiration. Any citizen petition challenging a generic application that has been pending for 18 months or more must be resolved by FDA within 120 days of filing, eliminating the tactic of using petition review timelines to block approval indefinitely.

• Insurers cannot remove a drug from coverage at annual renewal to force patients onto something else: Insurers currently use step-therapy requirements, which force patients to try cheaper alternatives before getting the drug their doctor prescribed. The step-therapy process includes an exception pathway, but insurers bypass it entirely by simply removing a drug from the formulary at the annual renewal rather than triggering a formal prior authorization review. Under this reform, any drug a patient has been continuously taking for 90 days or more must be covered at the same tier or lower for a full 12-month transition period after a formulary change, giving patients time to secure clinical exceptions through the 72-hour step-therapy exception process. Insurers cannot satisfy this requirement by placing a different drug on the same tier; the protection attaches to the specific drug the patient has been prescribed. Separately, insurers must disclose in annual rate filings the criteria used to place drugs on each formulary tier and whether manufacturer payments influenced placement.

What Changes for Each Group

Progressive Democrats

• The single biggest near-term win is the pharmacist workflow requirement. Right now, the legal right to know about a cheaper cash price exists on paper, but pharmacists exercised it only about 25 percent of the time. Requiring the dispensing system to generate a mandatory prompt means every commercially insured Progressive Democrat who walks up to a pharmacy counter will benefit from this disclosure without relying on whether that particular pharmacist remembers the rule.
• The statutory definition of "rebate" was the specific fix they demanded in round 1. The FTC documented that PBMs systematically reclassify rebate payments as administrative fees to escape disclosure obligations. That reclassification is now a statutory violation from the moment of enactment, before the rulemaking process even begins. This constituency views PBM rent-extraction as the core of a rigged system, and closing the reclassification route before PBMs have a regulatory gap to exploit is exactly the mechanism they wanted.
• The commercial rebate pass-through to 100 percent is now a statutory commitment, not a regulatory goal. Two election cycles from now, insurers must pass all rebates to patients at the counter. Progressive Democrats had to accept that the full pass-through does not arrive for six years, and that the 160 million working-age Americans who are commercially insured will see no drug price ceiling at all. The commercial market list price structure is untouched. Members who are underinsured or uninsured see no direct benefit from any mechanism in this policy area.
• Medicare beneficiaries in this constituency, who tend to skew older and who are more likely to be on a high-cost competition-free drug, get the most direct and immediate relief from expanded Medicare negotiation.

Moderate Democrats

• Every specific ask Moderate Democrats raised in round 1 was addressed: the statutory rebate definition closes the reclassification loophole, the civil penalty on formulary disclosure non-compliance ($100,000 per annual filing, plus $10,000 per day of delay) follows the hospital price transparency enforcement model they pointed to, and the formulary stability protection closes the non-medical switching gap that the step-therapy exception process left open. This is the reform they described wanting.
• The escalating commercial pass-through schedule resolves their core concern that 80 percent would become a permanent ceiling. Because the schedule is written into statute, it cannot be reset through a future administration's rulemaking. The pharmaceutical industry will lobby against it during the phase-in years, but the obligation is locked in legislatively.
• Moderate Democrats accept that this reform helps the insured more than the uninsured. Members without drug coverage, working low-wage jobs, or taking drugs with available therapeutic alternatives see no direct benefit from this policy area. The structural gap for the uninsured is real and acknowledged, and nothing in this proposal closes it.
• Members who have parents on Medicare Part D benefit most immediately from expanded negotiation. Members on ongoing commercial prescriptions benefit from the formulary stability protection and, several years out, from the rebate pass-through escalation.

Moderate Republicans

• The small-manufacturer carve-out was their specific request and was delivered exactly: manufacturers with under $200 million in annual U.S. net revenues are exempt from the quarterly PBM contract disclosure filing requirement. The PBM administering their products still has to file, so the reform's target (the three dominant PBMs) remains fully covered. This protects the emerging biotech developers that Moderate Republicans frame as legitimate engines of drug innovation.
• The IP protection clause and the 50-drug simultaneous negotiation cap give them the talking points they need for a primary defense. They can say the law explicitly confirms no effect on patent rights, and that active negotiations are capped at 50 at a time with a public annual queue. The cap is a ceiling, not a floor: at the IRA's first cohort pace of 10 drugs, it still allows an enormous expansion of negotiation scope. But it gives any co-sponsor a specific, verifiable limit to point to.
• The commercial pass-through escalation to 100 percent by year 6 is the friction point for this group. Moderate Republicans accepted the framing that the phase-in is calibrated to existing ACA medical loss ratio precedent, which is accurate. But pharmaceutical and insurer lobbying will argue through years 4 through 6 that the escalating requirement raises premiums for non-drug-using enrollees. Moderate Republicans accepted a six-year window for defense, not a permanent resolution of the argument.
• Self-employed members and small business owners buying their own insurance benefit from the pharmacist workflow requirement and, over time, from the commercial pass-through escalation. Members who invest in pharmaceutical or biotech companies face more regulatory constraint in the PBM pricing chain.

Conservative Republicans

• The IP protection clause and the 50-drug simultaneous negotiation cap were both delivered as specifically requested. Conservative Republicans view the IP clause as legally declaratory of existing law, but it removes a litigation talking point and gives them a visible firewall in the text of the statute. The negotiation cap and public annual queue prevent CMS from quietly expanding into simultaneous negotiations across the entire drug market.
• The small-manufacturer carve-out aligns with Conservative Republicans' framing that large pharmaceutical companies are different from the biotech developers they view as the legitimate private-sector engine of drug innovation. PBM reform also fits their genuine belief that intermediaries, not manufacturers, are extracting rents that damage patients and market signals.
• The core objection is unchanged. Medicare price negotiation backed by an escalating excise tax is, in Conservative Republicans' view, government price-setting with a compliance hammer attached, regardless of what the clause says about patent rights. The commercial pass-through escalation to 100 percent by year 6 is a new statutory mandate on commercial contracts with no sunset and no safety valve for premium impact. Many in this constituency believe these near-term cost reductions come at the cost of reduced future drug development investment, so they see themselves as net losers over a longer time horizon even when the immediate financial effect is positive. Their approval (44) reflects the procedural concessions but not a change in the underlying assessment of the mechanism.
• Conservative Republicans who are Medicare beneficiaries get the same benefit from Part D cost reductions as everyone else on Medicare. It does not change how they evaluate the mechanism.

Status Quo

The current system for healthcare market competition and administrative operation is characterized by three compounding failures: Certificate of Need laws in roughly 35 states [NCSL, 2024] allow incumbent hospital systems to formally oppose new competitors in regulatory proceedings, contributing to hospital markets where roughly 90% are classified as highly concentrated [Health Affairs, 2017]; antitrust enforcement has been episodic and reactive, with vertical consolidation absorbing nearly half of all physicians into hospital employment since 2012; and the multi-payer billing apparatus consumes approximately 34% of total healthcare expenditures in administrative overhead [JAMA, 2021], concentrated in prior authorization requirements that physician practices now average 39 per physician per week [AMA, 2024]. The Hospital Price Transparency rule has been in effect since 2021 but nearly half of hospitals remain non-compliant [HHS OIG, 2024], and even compliant data is difficult for patients to use. Scope-of-practice restrictions in roughly 11 states require nurse practitioners to operate under physician supervision regardless of local supply [AANP, 2024], directly limiting primary care access in rural and underserved areas.

What changed from round 1

• Price transparency binding estimate: multi-biller extension added. The round-1 estimate obligation bound only the facility of record. Every precedent, the No Surprises Act experience, the precedent brief, and all four constituencies, identified this as the primary failure point. Round 2 extends the binding estimate obligation to all entities whose services are ordered at scheduling, with coordination responsibility assigned to the ordering facility. If a sub-provider (anesthesiology group, radiology practice, pathology lab) does not return cost information within 24 hours of scheduling, the ordering facility must flag the gap in writing and the patient's out-of-pocket liability for that entity is capped at the Medicare rate for the service.

• Price transparency mandatory schema added. The round-1 format requirement said "standardized format specified by HHS." The precedent brief showed that format flexibility is a consistent circumvention path: hospitals post files that technically comply but are structured differently enough that no cross-facility comparison is possible. Round 2 specifies a mandatory field-level schema (CPT code, MS-DRG code, gross charge, payer-negotiated rate, Medicare rate, cash price, date effective) as a statutory requirement, not a regulatory one. CMS publishes the schema within 180 days of enactment. Deviation from the schema at any required field is non-compliance, even if the file is otherwise posted.

• Prior authorization TPA compliance gap closed. The round-1 provision covered insurers with 10,000 or more enrollees. An estimated 60 to 70 percent of employer-sponsored plan enrollees are in self-insured ERISA plans administered by third-party administrators (TPAs). The carrier may meet the format requirement while the plan sponsor retains discretion over clinical criteria, which the format mandate does not reach. Round 2 adds explicit language: where a TPA administers a self-insured ERISA plan, both the TPA and the plan sponsor are separately obligated under the prior authorization standards. The plan document may not delegate clinical criteria authority to a party not covered by the mandate.

• Administrative-denial clock restart closed. The round-1 text ran the 72-hour clock from first submission. Insurers exploited this by issuing "administrative" denials citing missing documentation, restarting the clock without triggering the clinical review requirement. Round 2 specifies that the 72-hour clock begins at first electronic submission and does not restart for supplemental documentation requests. Supplemental documentation requests must be submitted as a single complete list within 8 hours of initial submission; piecemeal requests are prohibited. Provisional approvals with conditions attached count as denials for purposes of the external review right.

• Antitrust geographic market definition locked. The round-1 provision defined the relevant geographic market as the county or the acquirer's own strategic planning service area, whichever is larger. This let the acquirer write its own market definition. Round 2 makes CMS Hospital Referral Region (HRR) the statutory default geographic market. Acquirer strategic planning documents may be used as secondary evidence to expand the market definition but cannot shrink it below the HRR boundary. This change satisfies Moderate and Progressive Democrats who want the mechanism to work, Moderate Republicans who want predictable outcomes, and Conservative Republicans who want a narrower but well-defined trigger.

• Antitrust HHI safe harbor added. Per Conservative Republican and Moderate Republican requests, and to address the concern that rural community hospital partnerships in low-population markets should not trigger federal review when the alternative is no hospital, Round 2 adds a safe harbor: acquisitions in markets where the Herfindahl-Hirschman Index (HHI) before the transaction is below 1500 (unconcentrated by DOJ standards) are exempt from the notification requirement. Markets above 2500 HHI trigger enhanced review. This targets the mechanism at actual consolidation problems while protecting rural-monopoly-by-necessity arrangements.

• Antitrust contractual integration trigger added. Management services agreements, clinical affiliation agreements, and joint operating agreements between a health system with 30 percent or more HRR market share and a physician group above five physicians (revised down from ten to close the pre-positioning circumvention) or an outpatient facility, where the agreement grants the health system revenue sharing, scheduling authority, or clinical criteria authority, are subject to the same notification requirement as formal acquisitions if the annual revenue involved exceeds $5 million. This closes the most documented circumvention pattern without requiring a new substantive legal standard.

• CON rural access standard replaced. The round-1 rural cross-subsidy (Medicaid-agency-administered volume floor) has no state-level precedent and requires administrative infrastructure that does not exist in most states within a five-year window. Round 2 replaces it with a facility licensure condition: new facilities in counties under 50,000 residents must, as a condition of initial licensure, document a defined service radius that includes zip codes designated as health professional shortage areas and demonstrate that they will accept patients from within that radius without payer discrimination. Compliance is audited by CMS as part of the existing Medicare conditions of participation survey cycle. Facilities that maintain compliance receive priority NHSC site designation. Facilities found out of compliance after three years face enhanced Medicaid matching recapture for the state.

• CON second federal lever added. Moderate Republicans correctly identified that in states with low enhanced Medicaid matching dependence, the matching condition alone may be insufficient. Round 2 adds a parallel Medicare quality reporting condition: states that maintain CON requirements beyond the five-year window for facility types prohibited under the reform are ineligible for the Medicare Quality Incentive Payment bonus pool (a 0.5 percent add-on to base Medicare payment rates for qualified providers in qualifying states). This creates a second federal pressure point that reaches hospitals whose Medicaid volume is low but whose Medicare revenue dependence is high.

• Prior auth sunset clause added. Per Conservative Republican request, Round 2 adds a seven-year sunset to the prior authorization ERISA mandate, with a mandatory statutory review in year six that requires Congress to affirmatively extend or modify the mandate rather than allowing it to persist by inertia. The sunset does not apply to the format standardization requirement, only to the mandate that ERISA plan sponsors comply with the clinical criteria standards.

• Prior auth denial rate monitoring provision added. The precedent brief identified a documented pattern: when negotiated rates become publicly visible, some insurers respond by tightening prior authorization as an indirect cost-containment mechanism, replacing price opacity with utilization control. Round 2 adds a statutory monitoring provision: HHS must publish annual prior authorization denial rates by insurer, disaggregated by service category, and must flag any insurer whose denial rate increases by more than 15 percent in any calendar year following mandatory rate transparency publication. Flagged insurers are subject to an automatic audit under the prior authorization compliance framework.

• Antitrust lookback provision added. The CON-antitrust cross-component gap: following CON repeal, new entrants are acquired by incumbent systems within 18 to 36 months, each acquisition below the physician-group threshold. Round 2 adds a 24-month lookback: a series of acquisitions by the same acquirer in the same HRR within a 24-month window are aggregated and treated as a single transaction for notification purposes. If the aggregated transaction crosses the notification threshold, each individual acquisition in the series retroactively triggers the filing obligation.

• Scope-of-practice prohibited restriction types defined. The round-1 provision said states may not impose "supervision requirements" on NPs and PAs in HPSAs and MUAs. States responded in practice by mandating collaborative practice agreements requiring physician co-signature on patient charts, technically not a "supervision requirement" but functionally identical. Round 2 defines the prohibited category explicitly: any state requirement that conditions an NP's or PA's legal authority to provide care on a physician's signature, co-signature, standing order, or real-time communication, for a patient encounter within a federally designated HPSA or MUA, is preempted. Collaborative practice agreements for quality improvement purposes (retrospective chart review, consultation protocols) are not preempted.

• Scope-of-practice telemedicine boundary clarified. Round 2 adds explicit language: an NP or PA licensed in a full-practice-authority state providing telemedicine to a patient physically located in an HPSA or MUA in a restricted state practices under the federal floor, not the restricted state's law, for purposes of supervision requirements. State licensing at the distant site is unaffected; only supervision requirements are preempted.

• Volume floor per licensure category clarified. The precedent brief identified that the 20% Medicaid volume floor applied as a blanket requirement across all facility types is a barrier for specialty facilities where Medicaid volume is structurally low (e.g., elective orthopedics) while being easily met by NP-led primary care clinics. Round 2 specifies that the service radius compliance condition for rural facilities is assessed per licensure category (primary care, acute inpatient, specialty outpatient, diagnostic imaging, surgical) using CMS cost report data for the relevant category rather than total facility volume.

Will this hold?

Political sustainability: The round-2 changes significantly improve the coalition picture for the prior authorization and antitrust components. The TPA plan sponsor fix is politically viable because it expands federal reach using an authority (ERISA) that is already firmly established and using a mandate (faster prior auth decisions) that physicians, patients, and employers nominally support. The sunset clause gives Conservative Republicans a defined exit ramp rather than a permanent confrontation. The HHI safe harbor defuses the "rural hospital crushed by federal antitrust" attack because it is explicit and quantified, not a discretionary agency judgment. The CON second lever (Medicare quality bonus pool) adds a pressure point that works in high-Medicare, low-Medicaid states, which is where the original lever was weakest.

The attack surface that persists: the contractual integration trigger is the most exposed flank. Hospital systems and their lobbying infrastructure (American Hospital Association, Federation of American Hospitals) will characterize it as requiring FTC notification for ordinary business contracts, which is technically accurate even if it misses the competitive effect. Progressive Democrats will also pressure this bill as an incomplete half-measure if it advances without companion drug pricing or coverage legislation, and that pressure will increase as the mechanism gets credited with improving price transparency without reducing what people actually pay.

The antitrust lookback provision will face legal challenge. A retroactive filing obligation on individually below-threshold transactions is novel; the FTC will need to be prepared to defend it in the first contested case, and that case will likely determine whether the provision survives in practice.

Structural dependency: The CON-antitrust coupling (noted in round 1) is now explicit in the statute and remains the primary structural risk. Round 2 adds a second dependency: the prior authorization monitoring provision depends on the price transparency machine-readable rate data being actually usable (the schema compliance) before HHS can compare denial rate changes to rate publication events. If schema compliance lags, the monitoring provision lacks its reference point. This is a second-order dependency but worth tracking: schema enforcement (quarterly CMS audits, public violation reports) must come before the monitoring provision's baseline year can be established.

Status Quo

Medicare explicitly excludes custodial long-term care, covering only limited skilled nursing following a qualifying hospital stay of at least three consecutive days, up to 100 days per benefit period. Medicaid covers custodial care in nursing homes and at home, but only after individuals have spent down assets to roughly $2,000, enforced through a five-year look-back on prior asset transfers. The private long-term care insurance market, which once had more than 100 carriers, has contracted to fewer than a dozen as insurers underestimated claim rates and exited; fewer than 50,000 new policies were sold in 2020 [AALTCI, 2021], and many existing policyholders have received premium increase notices of 50% or more. A private nursing home room cost a national median of $127,750 per year in 2024 [Genworth/CareScout, 2024], a figure that exceeds median household income and that most American families have no adequate mechanism to finance.

What changed from round 1

• Reinsurance trigger definition closed: The $150,000 reinsurance trigger is now defined in statute as cumulative paid claims, not calendar benefits. This closes the front-loaded product design circumvention that the precedent brief flagged and that three constituencies independently identified as a risk.

• Minimum loss ratio added: Certified LTC insurers must maintain a minimum loss ratio (MLR) of 80% of premiums paid in claims as a condition of reinsurance access. Without this floor, the federal backstop would subsidize products that serve insurer margins more than policyholder need. The precedent brief identified bundled-product arbitrage as the analogous risk; an MLR requirement addresses it directly.

• Fund capitalization decoupled from Medicaid savings projection: The reinsurance fund is now capitalized at $5 billion over 10 years from direct appropriations, with Medicaid savings treated as a supplementary top-up rather than the primary funding source. A $2 billion contingency reserve is appropriated separately; it activates automatically if Medicaid savings in years 1 to 3 fall below 40% of projection. This breaks the feedback loop (premium shock reduces enrollment, reduces savings, worsens solvency) that both the precedent brief and the viability feedback identified as the primary structural risk.

• Medicaid asset floor raised to $85,000 per individual: The base floor is raised from $75,000 to $85,000 per individual ($170,000 per couple). In exchange, the floor is given a statutory cap: it cannot be raised by regulation, only by Act of Congress. CPI indexing continues with an annual cap of 2%. This is the negotiated compromise between the Conservative Republican concern about regulatory escalation and the Progressive Democrat concern that $75,000 is insufficient protection in high-cost states.

• Home care workforce grant anti-offset provision added: The statute now explicitly defines the wage supplement as additive to total baseline compensation, not just baseline hourly wage. Providers must demonstrate that total worker compensation (wages plus benefits plus scheduled hours) rises by at least 75% of the grant-funded wage supplement. Annual provider-level audits enforce this. A 75% clawback applies if total compensation fails the threshold.

• Home care workforce grant sustainability requirement added: States must submit a post-grant sustainability plan as a condition of receiving year-1 grant funds. The plan must identify the state revenue source, either legislative appropriation or Medicaid rate formula adjustment, that will maintain the wage supplement past year five. States without an approved sustainability plan receive grant funds on a provisional basis only, with full disbursement contingent on plan approval within 18 months of enactment.

• Wage supplement ceiling indexed to inflation: The $4/hour ceiling on direct care worker wage supplements is now indexed to the CMS home- and community-based services (HCBS) cost index rather than held flat. This addresses the Progressive Democrat concern that the real value of the supplement would erode to roughly $3.20 by year five.

• Insurance desert fix elevated to statute: HHS is now required by statute, not just urged by feasibility guidance, to publish a state-by-state certified product availability report within 12 months of enactment. If any state has fewer than two certified products available, HHS must initiate a competitive procurement to bring at least one additional certified product to market in that state within 24 months. HHS may contract directly with an insurer of last resort for states where the private market remains absent after 24 months of procurement.

• Contingency mechanism for fund solvency adds congressional review: Automatic premium adjustment authority for certified insurers now triggers a mandatory 90-day congressional review period before any adjustment takes effect. CBO and OIG still report; Congress now has a formal window to act. This addresses the Conservative Republican objection that automatic adjustments without legislative oversight are an open-ended spending commitment.

• HCBS benefit floor indexed separately from nursing facility index: The certified product benefit floor for home- and community-based services is indexed to the CMS HCBS cost index rather than the nursing facility cost index. This addresses the cross-component risk the precedent brief identified: if the workforce grant raises home care wages, using the nursing facility index to adjust the HCBS benefit floor would cause the floor to lag behind actual home care costs, creating a coverage adequacy gap in grant-participating states.

Will this hold?

Political sustainability: The round-2 changes improve durability at the margins, primarily by giving each of the two center constituencies something concrete to defend. Moderate Republicans can point to the contingency reserve as proof the fund is actuarially sound and the 90-day review as proof there is legislative oversight. Moderate Democrats can point to the insurance desert procurement requirement in statute, the honest fund capitalization, and the anti-offset workforce provision. Neither of these wins is glamorous campaign material, but both reduce the surface area for the "program failure in year 5" attack story that was round 1's biggest vulnerability. The statutory cap on the Medicaid floor is the most durable political fix in this round. It converts the primary Conservative Republican attack line ("stealth entitlement expansion") into a legislative question rather than an administrative one: a future Congress that wants to raise the floor has to have that debate publicly. The remaining vulnerability is Conservative Republican base motivation. A 52% approval from a constituency with 38% political weight means roughly half of that constituency votes yes, but organized opposition from the other half can still generate a loud campaign attack. The most likely attack vector remains the fund size: "a $7 billion federal bailout for insurance companies" is a cleaner attack line than the round-1 version because the decoupled capitalization makes the commitment more transparent. Moderate Republican incumbents will need a practiced response: "the fund is a backstop for policyholders, not a subsidy for insurers, and the MLR requirement means 80 cents of every premium dollar goes to claims or we pull certification."

Structural dependency: The fund's primary structural dependency from round 1 has been addressed: solvency no longer depends on Medicaid Partnership savings materializing at projected scale or timing. The new structural dependency is the 90-day congressional review requirement for automatic premium adjustments. If Congress becomes paralyzed in a given review period (government shutdown, recess, or simple gridlock), the review window may lapse without action, and the automatic adjustment would proceed by default. This is not a catastrophic failure mode, but it means the "congressional oversight" protection is somewhat procedural. A second dependency: the insurance desert insurer-of-last-resort authority requires HHS to build or borrow a competitive procurement infrastructure it does not currently have. If HHS cannot operationalize this within 24 months, states with fewer than two certified products will have a statutory guarantee that is unenforceable in practice for a period. The OPM partnership recommendation above is the fix; whether it is pursued depends on executive branch coordination that is not mandated in statute.

What the next iteration should change

This section is omitted. Verdict is Pass.

This policy area reforms how Americans pay for long-term care by creating a federal reinsurance backstop for private insurance, protecting more assets before Medicaid kicks in, expanding HSA savings for older workers, and investing in the home care workforce.

What Changes

• Private long-term care insurance becomes viable again: The private LTC insurance market has shrunk from over 100 carriers to fewer than a dozen because insurers could not price policies sustainably against unpredictable long-term claims. A Federal Long-Term Care Reinsurance Fund, capitalized at $5 billion over 10 years, covers 80% of a policyholder's costs once cumulative claims paid by the insurer exceed $150,000. Insurers keep 20% exposure so they retain an incentive to manage costs. To receive reinsurance access, a product must cover at least three years of care at a minimum $150 per day, cover both nursing home and home care, exclude pre-existing conditions after a 12-month waiting period, and pay at least 80 cents of every premium dollar in claims. A separate $2 billion contingency reserve activates automatically if Medicaid savings projections fall significantly short in the first three years.

• Families no longer have to spend down to near-nothing before Medicaid helps: Right now, an individual must exhaust assets to roughly $2,000 before Medicaid covers nursing home or home care costs. This forces middle-class families to impoverish themselves. A federal floor of $85,000 per individual ($170,000 per couple) is set in statute, and states cannot go lower. The floor is indexed to inflation annually, capped at 2% per year. Critically, the floor cannot be raised above $85,000 by regulation: any future increase requires an Act of Congress. Additionally, anyone who buys a federally certified LTC policy gets dollar-for-dollar Medicaid asset protection: for every dollar of private insurance benefits received, they can keep an equivalent dollar of personal assets above the floor before Medicaid spend-down applies.

• Older workers can save more for long-term care through HSAs: Health Savings Accounts currently have annual contribution limits and use restrictions that make them a poor long-term care savings tool. Adults 50 and older get an additional $3,600 per year LTC-designated catch-up contribution tier. HSA funds can pay premiums for certified LTC insurance products without the existing age-indexed cap that restricts deductibility for the people most likely to need coverage soon. HSA balances can also roll over to a spouse for LTC-specific use, removing the current tax penalty.

• Home care workers get a real wage increase, not one that providers can game away: Direct care worker turnover runs roughly 65% annually, driven largely by wages that are among the lowest in the economy. Every prior federal attempt to raise home care wages has been undercut by providers reducing benefits or cutting scheduled hours to offset the required wage increase. A five-year, $2.5 billion federal grant program funds wage supplements of up to $4 per hour (indexed annually to the federal home care cost index). The supplement is defined in statute as additive to total compensation, wages plus benefits plus scheduled hours. Providers face an annual audit and a 75% clawback of grant funds if total worker compensation does not rise by at least 75% of the supplement. States must submit a sustainability plan identifying how they will maintain the wage improvement after the grant ends; they receive only half their year-one funds until the plan is approved.

• States where the LTC insurance market has already collapsed get a fix: In states where the private LTC market has contracted severely, the reinsurance backstop is theoretical because there is no certified product to buy. HHS must publish a state-by-state product availability report within 12 months of enactment. If any state has fewer than two certified products, HHS must run a competitive procurement to bring at least one more to market within 24 months. If no insurer responds after 24 months, HHS can contract with an insurer of last resort to offer a certified product at actuarially justified rates backed by the reinsurance fund.

What Changes for Each Group

Progressive Democrats

• The 80% minimum loss ratio requirement is the most concrete concession to the concern that private insurers caused the LTC market failure and should not be rewarded with a federal backstop while continuing to prioritize margins over claims. Eighty cents of every premium dollar must be paid in claims, and HHS publishes annual loss ratio reports in machine-readable format. An insurer that falls below the threshold loses reinsurance access. Progressive Democrats see this as inadequate (they wanted 85%) but it is a binding, enforceable floor where there was none before.
• The home care workforce supplement retains its real value: the $4/hour ceiling is indexed to the CMS home care cost index, not held flat. Without indexing, the supplement would have eroded to roughly $3.20 in real terms by year five. Direct care workers are a core Progressive Democrat constituency, and this fix directly protects their wages over the grant's full duration.
• The Medicaid asset floor rose from $75,000 to $85,000 per individual. In states where nursing home costs exceed $120,000 per year, $75,000 represented less than eight months of protected assets before spend-down began. $85,000 is better, but still falls short of a full year of protection in the highest-cost states, and Progressive Democrats are clear that this does not reach the near-retirement, low-income adults who have no HSA coverage and cannot afford a certified premium at any price. That family is still outside this bill.
• What Progressive Democrats accept: the entire delivery mechanism runs through private insurers, which they believe are the same industry that caused the LTC market failure. The reinsurance fund provides those insurers with a federal backstop. The MLR requirement and the annual transparency reports are the price of admission, but the structural critique remains: this is a market-compatible fix for a market failure, not a universal benefit. The statutory cap on the Medicaid floor also means that any future Congress that wants to raise protection for low-income families must win a legislative fight from scratch rather than adjusting administratively.

Moderate Democrats

• The reinsurance fund is now honestly capitalized. The original design tied the fund's solvency to Medicaid savings projections that independent analysis suggests arrive four to six years after enrollment and at roughly $74 per participant on average. That feedback loop, where premium increases reduce enrollment, reducing savings, worsening solvency, is eliminated. The $5 billion direct appropriation is the primary vehicle; Medicaid savings flow in as a supplementary top-up if and when they materialize.
• The insurance desert fix now has teeth. HHS is required by statute, with a 24-month deadline, to ensure at least two certified products are available in every state. If no insurer enters voluntarily, HHS can contract one in as an insurer of last resort. Families in states with collapsed LTC markets can rely on this as an actual product guarantee, not an aspiration.
• The workforce grant anti-gaming provision and the post-grant sustainability requirement address both documented failure modes from prior federal wage pass-through programs: providers reducing benefits to offset mandated wage increases, and wages collapsing when federal funds run out. Moderate Democrats accept that a five-year grant with a sustainability plan is better than nothing, while knowing that whether wages hold in year six depends on state politics.
• What Moderate Democrats accept: the statutory cap on the Medicaid floor is the Conservative Republican price for the higher $85,000 starting point. Future Congresses cannot raise the floor administratively; they have to fight for it legislatively. Moderate Democrats agreed to this constraint because the alternative was a lower floor or no deal. The near-retirement, low-income gap remains: the person who cannot afford a certified product and has no assets to protect under the Medicaid floor is still not in this bill.

Moderate Republicans

• The $2 billion contingency reserve, appropriated as mandatory spending, eliminates the scenario that most worried Moderate Republicans in round one: a fund that looks solvent at launch but triggers premium increases on certified products in years four to six when Medicaid savings do not materialize on schedule. The reserve activates automatically if savings fall below 40% of projection. Moderate Republicans can now defend the fund's solvency without relying on optimistic projection assumptions.
• The 90-day mandatory congressional review before any automatic premium adjustment takes effect on certified products gives Moderate Republicans a concrete oversight mechanism. An automatic administrative adjustment that opponents could describe as unchecked is replaced by a formal congressional window, including a concurrent resolution override. This is the kind of legislative guardrail that makes a vote defensible to a center-right constituency.
• The workforce grant maintenance-of-effort requirement is narrowly scoped: states must not cut existing Medicaid home care reimbursement base rates, but they retain full authority to restructure how HCBS services are delivered. Moderate Republicans had objected that a broadly written MOE would override state Medicaid policy; the narrow scope addresses that concern.
• What Moderate Republicans accept: the total federal commitment is $7 billion ($5 billion fund plus $2 billion contingency reserve), which is more transparently expensive than the round-one framing. The insurer-of-last-resort authority gives HHS a new procurement capability with no direct CMS precedent, which creates execution risk and a new federal-state contracting relationship that Moderate Republicans view with some skepticism. They are comfortable with the FEHBP analogy but acknowledge the operational build is real.

Conservative Republicans

• The statutory cap on the Medicaid asset protection floor is the single most significant Conservative Republican win in this proposal. The floor cannot be raised above $85,000 per individual by regulation or administrative action; any increase requires an Act of Congress. This converts what could otherwise be described as a stealth entitlement expansion into a legislative question: a future Democratic administration cannot quietly adjust the floor upward. Conservative Republicans can point to the cap as a binding constraint, not a promise.
• The 90-day mandatory congressional review before any automatic premium adjustment applies to certified products gives Conservative Republicans a formal override window. They can mobilize opposition through a concurrent resolution rather than watching an executive adjustment go into effect while organizing.
• The HSA expansion is the component most compatible with Conservative Republican preference for private, individual savings as the primary LTC financing mechanism. The $3,600 LTC-designated catch-up contribution tier and the removal of the premium deductibility cap for certified products expand private savings tools for near-retirement households. Conservative Republicans view the HSA component as the bill's most defensible element.
• What Conservative Republicans accept: the $85,000 per individual starting point is higher than they wanted. Their preferred approach was to cap the existing floor in place; the compromise raised the floor before capping it. The $7 billion total federal commitment (fund plus contingency reserve) is the most expensive new federal spending item in this policy area, and Conservative Republicans believe the private market should be pricing this risk. They are accepting the reinsurance mechanism as a market-compatible structure while noting that $7 billion over 10 years is not a small bet that the market cannot solve this on its own.

Status Quo

The Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) requires that insurers apply the same coverage rules to behavioral health as to medical and surgical care, but enforcement has been procedural rather than outcomes-based: plans self-certify compliance and regulators rarely audit the result. In practice, mental health providers are reimbursed at substantially lower rates than equivalent medical specialists [Milliman, 2023], which has pushed the majority of therapists and a substantial share of psychiatrists out of insurance networks entirely. State psychiatric bed capacity has fallen to 10.8 beds per 100,000 population [NASMHPD, 2023], a historic low, and drug overdose deaths totaled approximately 79,000 in 2024 [CDC, 2024].

What changed from round 1

• Baseline measurement moved to enactment date: The anti-reduction prohibition for behavioral health provider networks now uses a baseline provider count measured at the date of enactment, not at the date the reimbursement floor takes effect. This closes the pre-emptive network reduction window that the precedent brief identified as the primary circumvention risk. Plans cannot shrink their networks in the 30-month window between enactment and the floor's effective date and then use that smaller network as the protected baseline.

• TPA joint liability added in statute: Third-party administrators (TPAs, the organizations that handle claims processing and plan administration for self-insured employer plans) operating plans with more than 10,000 covered lives are now explicitly co-responsible parties under ERISA for the accuracy of Comparative Analysis Reports (CARs). Joint and several liability for civil monetary penalties arising from materially false CARs is established in statute, not left to rulemaking. This closes the binding gap the precedent brief and viability check both flagged as the enforcement component's most significant structural flaw.

• Provisional CAR template within six months: The statute now requires HHS to publish a provisional Comparative Analysis Report template within six months of enactment. Plans must file annual denials data, authorization timelines, and reimbursement ratios against the provisional template immediately, using existing benefit categories. The provisional template is replaced by the final methodology once the 18-month rulemaking is complete. This does not advance enforcement before the methodology is settled, but it gives HHS 18 months of real plan data to calibrate the final rule, and it gives Progressive Democrats and Moderate Democrats visible data-collection activity in year one. Conservative Republicans can frame it as accountability starting on day one.

• CPT crosswalk methodology anchored in statute: The statute specifies that the crosswalk methodology shall be RVU-based (using Medicare relative value units as the comparator anchor) and shall fix specific comparison pairs for the most-used behavioral health CPT codes, rather than leaving the methodology entirely to rulemaking. The MHPAEA Oversight Board refines the pairs within that statutory anchor; it does not redesign the approach. This reduces the Administrative Procedure Act litigation surface area identified by the precedent brief, where multiple defensible methodologies diverge by 15 to 25 percent and create years of implementation delay.

• AOT technical assistance program added: A federal Assisted Outpatient Treatment (AOT) Technical Assistance Program is established through a $75 million appropriation from the HHS discretionary budget, entirely separate from the Crisis Care Infrastructure Grant Program. The program funds states that want to develop or improve their AOT programs, covering court system integration design, due process framework development, outpatient wraparound service design, and data collection. No funds may be used to construct facilities or to expand the population subject to involuntary commitment beyond state-law thresholds in effect at enactment. This addresses Conservative Republicans' strongest single concern without touching the grant program guardrail or the involuntary commitment prohibition that Progressive Democrats require.

• Maintenance-of-effort condition added to Crisis Care grants: States receiving Crisis Care Infrastructure Grant Program funds must maintain state-funded behavioral health spending at no less than 90 percent of their average state behavioral health expenditure over the three fiscal years preceding enactment, as a condition of receiving year-two and subsequent disbursements. A hardship waiver is available for states that can document a documented general revenue shortfall exceeding 5 percent relative to their prior-year budget. This is standard practice for Medicaid grants and addresses the substitution risk identified by both the precedent brief and viability feedback from all four constituencies.

• Workforce retention incentive added: NHSC participants who remain in practice in a Mental Health Professional Shortage Area for five or more years beyond their required service obligation receive an additional $30,000 in supplemental loan repayment per qualifying year (up to three additional years). This targets the documented 40 percent post-obligation attrition rate. The cost is contained: only practitioners who have already fulfilled their initial obligation and remained in shortage-area practice qualify.

• Network participation counts added to CAR from year one: The CAR audit template, including the provisional template, shall require plans to report the number of contracted behavioral health providers per 1,000 covered lives, broken down by specialty and by geographic market. This metric must be included from year one, not introduced after the first enforcement cycle. Plans that raise reimbursement rates while shrinking networks pass rate-level audits but fail participation audits. Including both from the start closes the measurement gap the viability check's implementation analysis identified.

• Grant recipient workforce documentation required: Grant recipients under the Crisis Care Infrastructure Grant Program must submit, as a condition of year-two disbursement, a workforce plan documenting their behavioral health staffing pipeline, current vacancy rate, and wage levels relative to regional market rates. This prevents a scenario where infrastructure grants fund construction of inpatient beds that sit unstaffed because the recipient cannot hire at prevailing wages. New beds with no clinicians are not operational capacity.

• SAMHSA direct performance agreement bypass: SAMHSA is granted authority to enter direct performance agreements with individual programs in states that fail to pass federal performance accountability through to their subgrantees, including states that absorb a block grant reduction by cutting across all subgrantees proportionally rather than targeting poor performers. This creates a bypass mechanism when state administration is the weak link, converting the outcome contingency from a state-level lever into one that can reach the program level when necessary.

• Scored cost offset commissioned before floor vote: The statute directs HHS to commission, within 90 days of enactment, an actuarial analysis of projected emergency department diversion, reduced inpatient medical admissions, and justice-system cost offsets, to be completed and published before the reimbursement floor rule takes effect. This is not a mechanism change. It is a transparency commitment that materially affects the legislative coalition by converting the cost-reduction argument from an advocacy claim into a scored estimate.

Nothing else changed. No provision from the settled core has been reopened.

Will this hold?

Political sustainability: The coalition is more durable than round 1 but still fragile at the reimbursement floor. The floor's most dangerous political window remains year two to year three: rulemaking underway, premium increases visible, no network improvement yet materialized. Round 2 changes that window in two ways. First, the provisional CAR template means that published denial-rate data is available within twelve months of enactment, giving bill supporters a concrete ongoing deliverable to cite against repeal campaigns. Second, the scored cost offset analysis, published before the floor takes effect, converts the savings argument from a forecast to a scored estimate, which is harder for repeal campaigns to dismiss. The AOT Technical Assistance Program gives CRs something to defend alongside the enforcement and accountability provisions, which broadens the coalition slightly on the right. The most credible attack vector remains the insurance industry's "government rate-setting" framing; the congressional findings help floor managers but will not stop the advertising campaign. The right's second attack vector, the AOT exclusion from the grant program, is partially addressed by the technical assistance program, but CRs who wanted new coercive capacity will continue to use any high-profile violent incident involving an untreated severely mentally ill person as evidence that the bill left out what mattered most. That attack is durably available.

Structural dependency: The pre-existing structural dependency from round 1 holds: the reimbursement floor depends on the CPT crosswalk methodology, which depends on the MHPAEA Oversight Board being constituted and functional. Round 2 adds a default appointment mechanism (if the Secretary has not appointed a full Board within six months, the HHS and DOL chairs convene a provisional technical working group), which reduces the Oversight Board's status as the single point of failure. The new dependency introduced in round 2 is the provisional CAR template: HHS must publish a usable template within six months of enactment, which requires rulemaking to begin before enactment. If HHS treats the provisional template as a second-order priority, the data collection activity that PDs and MDs expect in year one does not materialize, and the political case for the bill in years one through three weakens. The provisional template is now a critical path item.

What the next iteration should change

This section is omitted because the verdict is Pass.

This policy area reforms the enforcement and funding of mental health and addiction treatment parity, moving from a law that exists on paper to one with teeth: mandatory audits, a reimbursement floor that brings behavioral health pay in line with physical health pay, and a federal infrastructure program to rebuild inpatient and crisis care capacity that was dismantled over decades.

What Changes

• Mandatory insurance audits with real penalties: Insurers today self-certify parity compliance and regulators rarely verify the result, so plans can maintain behavioral health denial rates and reimbursement levels far worse than for physical health services with no consequence. Under this reform, plans covering more than 10,000 people must submit annual reports documenting their denial rates, authorization timelines, and reimbursement ratios for behavioral health versus medical and surgical care. Any plan whose behavioral health denial rate exceeds its medical denial rate by more than 10 percentage points for two consecutive years is automatically referred for enforcement. The penalty is $10,000 per affected enrollee per year of violation, with no cap for large plans. Revenue from penalties flows into a dedicated enforcement fund that cannot be raided through the appropriations process.

• Third-party administrator accountability closed: Large employers typically do not administer their own health plans; they hire third-party administrators (TPAs) to handle claims and benefits on their behalf. Under current law, the TPA can produce a compliance report that makes the plan look compliant while the employer, who lacks internal data to check it, signs off. This reform makes TPAs co-responsible in statute, with joint and several liability for civil monetary penalties when compliance reports for plans with more than 10,000 covered lives are materially false. The employer can no longer be shielded by a TPA filing inaccurate data.

• Published compliance data for every plan: Every plan's annual compliance report, including denial rates, authorization timelines, reimbursement ratios, and contracted behavioral health providers per 1,000 covered lives broken down by specialty and geography, must be posted in a searchable, machine-readable federal portal within 60 days of submission. Parity analysis data is specified by statute not to be a trade secret, preventing plans from blocking disclosure on proprietary grounds.

• A reimbursement floor that makes behavioral health networks actually work: Mental health therapists, psychiatrists, and addiction counselors are reimbursed by insurers at roughly 20 to 30 percent below what equivalent physical health providers receive, making it financially irrational for most to accept insurance at all. That is why plans can claim to have adequate behavioral health networks on paper while patients wait months for an in-network appointment. This reform requires that any plan subject to parity law pay behavioral health providers at least 90 percent of what it pays equivalent medical providers in the same geographic market, phasing to full parity over three years. Plans are prohibited from shrinking their behavioral health provider networks to offset the rate increase, measured against the network size at the date this law is enacted, not at some later date after plans have had time to pre-emptively cut providers.

• Inpatient psychiatric and crisis care capacity rebuilt from scratch: The U.S. has eliminated more than 95,000 inpatient psychiatric beds since the 1960s, leaving emergency rooms and jails as the default system for people in acute mental health crisis. A five-year, $8 billion federal grant program funds states to build or expand inpatient psychiatric units, crisis stabilization units (short-term alternatives to emergency department holds), mobile crisis response teams, and Certified Community Behavioral Health Clinics that provide 24/7 crisis and outpatient services. Grants target the 25 states with the worst psychiatric bed ratios. States must maintain their own behavioral health spending at 90 percent of pre-grant levels to prevent federal dollars from substituting for state spending that would have happened anyway.

• More behavioral health providers, retained longer in the places that need them: Even if reimbursement rises, there are not enough licensed behavioral health providers to meet demand, particularly in rural and low-income areas. The National Health Service Corps expands its behavioral health scholarship and loan repayment programs by $600 million, with priority for shortage areas. Providers who stay in a shortage area for five or more years beyond their required service obligation receive an additional $30,000 per year in supplemental loan repayment for up to three additional years, directly addressing the pattern in which 40 percent of NHSC participants leave shortage-area practice once their initial obligation ends. Telehealth for behavioral health services is permanently authorized for Medicare and Medicaid patients.

• Federal grants tied to program outcomes, not just activity: Federal behavioral health block grants through SAMHSA have historically required states to report spending, not results. Under this reform, SAMHSA develops risk-adjusted outcome metrics for all funded programs within two years and, after a 24-month baseline period, ties continued funding to outcome trajectory. Programs in the bottom 10 percent face technical assistance review, then funding reductions if they do not improve. When a state responds to a funding reduction by cutting all programs proportionally rather than targeting poor performers, SAMHSA can bypass the state and enter direct performance agreements with individual programs.

• Federal support for states that want to improve court-supervised outpatient treatment programs: States that operate Assisted Outpatient Treatment (AOT) programs, which allow a court to order outpatient psychiatric treatment for individuals who meet a legal standard of danger to themselves or others, have no dedicated federal resource for program design. A separate $75 million program over five years provides technical assistance for court system integration, due process framework development, outpatient wraparound service design, and data collection. No funds may be used to expand the population subject to involuntary commitment beyond each state's existing legal thresholds, to build facilities, or to operate commitment programs.

What Changes for Each Group

Progressive Democrats

• The two structural holes in the reimbursement floor are closed. Under round 1, plans could have pre-emptively reduced their behavioral health provider networks in the 30 months between enactment and the floor's effective date, then used that smaller network as the protected baseline. The reform now measures the baseline at the date of enactment, eliminating that window. Progressive Democrats care about this because the floor was the reform they most needed, and a floor built on a pre-emptively shrunk network would have been a legal placeholder, not a functional guarantee.

• Third-party administrator liability is in statute, not left to rulemaking. The self-insured employer plan market, which covers most large-employer workers, could not be reached under prior enforcement approaches because TPAs controlled the compliance data while employers lacked the internal capacity to verify it. Progressive Democrats read the TPA gap as the mechanism by which large employers had effectively been exempt from parity law while low-income workers in small, fully insured plans faced tighter scrutiny. Closing it in statute changes that.

• Published denial-rate data appears within twelve months of enactment, not thirty. The provisional compliance report template, published by HHS within six months of enactment, requires plans to begin filing denial-rate and network data immediately under existing benefit categories. Progressive Democrats can point to that data while overdose deaths are still happening. Having concrete accountability deliverables in year one instead of year three matters to a constituency whose patience with "give enforcement time to work" arguments is exhausted.

• The AOT Technical Assistance Program is a concession Progressive Democrats will resist explaining to their base. Federal funding for AOT program design reads, in progressive advocacy communities, as federal legitimization of compelled psychiatric treatment, regardless of the guardrails. The no-funds-for-coercive-infrastructure rule is real, but the program exists and has a federal dollar figure attached to it. Progressive Democrats accept it because the overall package, including the reimbursement floor and the CCBHC expansion, is not achievable without Conservative Republican votes, and AOT technical assistance is the price of those votes. They are not happy about it.

Moderate Democrats

• Every item Moderate Democrats pushed for in the iteration process is in the final proposal. The maintenance-of-effort condition for crisis care grants uses exactly the standard applied to Medicaid: states must maintain their own behavioral health spending at 90 percent of the three-year pre-grant average, with a narrow hardship waiver requiring documented general revenue shortfalls exceeding 5 percent. Moderate Democrats care about this because they have watched federal infrastructure dollars substitute for state spending in program after program, producing net-zero new capacity rather than the additional investment the dollar figure implies.

• Organizations building toward full CCBHC certification are eligible for grant funds from year one, not only after the 18-to-24-month certification process completes. The previous CCBHC expansion under the American Rescue Plan Act was largely captured by already-certified sites because the grant windows were too short for new sites to complete certification. Allowing pre-certification entities in from day one means underserved communities can receive services from a growing clinic before it holds a federal certification, rather than waiting two years for paperwork to complete.

• SAMHSA can now bypass state health agencies that fail to hold their subgrantees accountable. The typical failure mode is a state that responds to a block grant accountability reduction by distributing the cut proportionally across all programs, protecting poor performers from the consequence intended only for them. SAMHSA can now go directly to the program level when state administration is the weak link. Moderate Democrats care about this because they have watched block grant accountability mechanisms get absorbed at the state level for decades.

• The scored actuarial analysis of emergency department and incarceration cost offsets is commissioned within 90 days of enactment and published before the reimbursement floor takes effect. Moderate Democrats will have to defend this bill's $8.7 billion price tag in the 30-month window when premium increases are visible and network improvement has not yet materialized. The cost offset analysis converts the downstream savings argument from an advocacy claim into a scored estimate they can cite in that defense.

Moderate Republicans

• The reimbursement floor is defined in the statute's congressional findings as parity, not price regulation. The floor requires plans to pay behavioral health providers the same proportion of their own medical fee schedule that they apply to medical services. The government is not setting a price list; it is requiring that the plan's own pricing standard apply consistently across physical and behavioral health. The MHPAEA Oversight Board reports annually to Congress on the crosswalk methodology's observed effect on premiums, giving Moderate Republicans ongoing published data to use in floor debates when the "government rate-setting" attack is made. They know the attack will be made regardless.

• The comparison methodology that determines what "equivalent" means for behavioral health versus medical billing is anchored in statute at the Medicare relative value unit framework, with specific comparison pairs for the most commonly billed behavioral health procedure codes. Under prior versions of the rule, insurers could challenge any methodology choice as arbitrary agency action because multiple defensible methodologies existed and produced results diverging by 15 to 25 percent. Fixing the anchor in statute narrows the litigation surface considerably. Moderate Republicans flagged this as the floor's most vulnerable legal point; round 2 addressed it directly.

• Premium increases of 1 to 2 percent are still real and will still be visible to constituents. The congressional findings help floor managers but do not stop advertising campaigns calling this government rate-setting. Moderate Republicans are accepting a provision their own insurance-industry supporters will run against, in exchange for a mechanism they believe will reduce emergency room and incarceration costs over time. They want the scored cost offset analysis before the floor vote to have a number to point to.

• Rural and suburban Moderate Republican constituencies benefit from the NHSC retention incentive, which keeps providers in shortage areas beyond their initial service obligation, and from the permanent telehealth authorization, which provides in-network access for patients in areas where in-person behavioral health care is not available.

Conservative Republicans

• The Assisted Outpatient Treatment Technical Assistance Program is the single most important concrete concession to Conservative Republicans in this proposal. States that operate or want to develop court-supervised outpatient treatment programs for severely mentally ill individuals have had no dedicated federal resource for program design, court integration, or due process framework development. Conservative Republicans believe that the absence of a meaningful AOT option in most states is why dangerously ill people cycle through emergency rooms, jails, and streets rather than receiving structured treatment. This program addresses that concern with a federal commitment, even if it does not fund coercive infrastructure. The program is funded separately from, and cannot be reduced by cutting, the Crisis Care Infrastructure Grant Program.

• The maintenance-of-effort condition closes a substitution gap Conservative Republicans explicitly named: states that receive federal crisis care grants can no longer reduce their own behavioral health spending and pocket the federal dollars as state budget relief. The 90-percent floor with a hardship waiver for genuine fiscal emergencies is the standard Medicaid uses and is difficult to characterize as federal overreach.

• Conservative Republicans are still voting for a reimbursement floor their base will call a government rate mandate. The congressional findings language and the annual premium transparency report are useful for floor debate, but they do not change what the mechanism does: it requires plans to pay behavioral health providers at a specified percentage of their own medical rate. That is an intrusion into private contracting that Conservative Republicans oppose on principle, and they know the insurance industry will fund campaigns making exactly that argument.

• The AOT Technical Assistance Program provides federal support for program design, court integration, and due process frameworks. It does not fund new coercive capacity, does not authorize involuntary commitment beyond each state's existing legal thresholds, and does not fund any facilities. Conservative Republicans who wanted new federal authority for expanded AOT or dedicated facility funding got neither. They are accepting the technical assistance program as the maximum available concession, because removing the reimbursement floor or the crisis care grant program's AOT exclusion would lose the votes needed to pass anything.